Literature DB >> 6264897

Efficacy of a virion envelope herpes simplex virus vaccine against experimental skin infections in hairless mice.

R J Klein, E Buimovici-Klein, H Moser, R Moucha, J Hilfenhaus.   

Abstract

Hairless mice were immunized with herpes simplex virus type 1 (HSV-1) envelope antigen (EAG), EAG in association with polyriboinosinic . polyribocytidylic acid-poly-L-lysine complexed with carboxymethylcellulose (PICLC), and inactivated purified HSV-1 (VAG). After 2 weeks the mice were challenged by a percutaneous HSV-1 infection in the orofacial (OF) or lumbosacral (LS) skin area. Following immunization a consistent cell-mediated immune response was observed in all immunized mice, although the humoral immune response was very low, or not detectable. After challenge, a marked secondary humoral and cell-mediated immune response developed in all immunized mice, and the animals were protected against the development of skin lesions and the fatal outcome of infection. However, the establishment of latent infections in the sensory ganglia was not prevented by the immunization procedure.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6264897     DOI: 10.1007/bf01314437

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  14 in total

1.  Herpes simplex virus vaccines.

Authors:  T G Wise; P R Pavan; F A Ennis
Journal:  J Infect Dis       Date:  1977-11       Impact factor: 5.226

2.  Radioimmunoassay of herpes simplex virus antibody: correlation with ganglionic infection.

Authors:  B Forghani; T Klassen; J R Baringer
Journal:  J Gen Virol       Date:  1977-09       Impact factor: 3.891

3.  Protection of guinea pigs against primary and recurrent genital herpes infections by immunization with live heterologous or homologous Herpes simplex virus: implications for a herpes virus vaccine.

Authors:  M Scriba
Journal:  Med Microbiol Immunol       Date:  1978-11-17       Impact factor: 3.402

4.  The association of herpesvirus type 2 and carcinoma of the uterine cervix.

Authors:  W E Rawls; W A Tompkins; J L Melnick
Journal:  Am J Epidemiol       Date:  1969-05       Impact factor: 4.897

5.  Efficacy of a nucleic acid free herpetic subunit vaccine.

Authors:  R Cappel; F de Cuyper; F Rickaert
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

6.  Immunogenicity of subviral herpes simplex virus preparations. I. Formation of neutralizing antibodies in different animal species after administration of herpes simplex virus solubilized antigens.

Authors:  L Kutinová; V Slichtová; V Vonka
Journal:  Arch Virol       Date:  1979       Impact factor: 2.574

7.  Detection by complementation of defective or uninducible (herpes simplex type 1) virus genomes latent in human ganglia.

Authors:  S M Brown; J H Subak-Sharpe; K G Warren; Z Wroblewska; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1979-05       Impact factor: 11.205

8.  Protection from oral herpes simplex virus infection by a nucleic acid-free virus vaccine.

Authors:  E N Kitces; P S Morahan; J G Tew; B K Murray
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

9.  Oncogenic transformation of hamster embryo cells after exposure to inactivated herpes simplex virus type 1.

Authors:  R Duff; F Rapp
Journal:  J Virol       Date:  1973-08       Impact factor: 5.103

10.  Prepubertal vaccination of mice against experimental infection of the genital tract with type 2 herpes simplex virus.

Authors:  G R Skinner; D R Williams; A W Moles; A Sargent
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

View more
  12 in total

1.  Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis.

Authors:  G R Skinner; C Fink; J Melling; C Wiblin; B Thornton; J Hallworth; W Gardner; P McLeish; C Hartley; A Buchan
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

Review 2.  The pathogenesis of acute, latent and recurrent herpes simplex virus infections.

Authors:  R J Klein
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

3.  Glycoprotein D protects mice against lethal challenge with herpes simplex virus types 1 and 2.

Authors:  D Long; T J Madara; M Ponce de Leon; G H Cohen; P C Montgomery; R J Eisenberg
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

4.  Viral vaccines: the use of currently available products and future developments.

Authors:  E Norrby
Journal:  Arch Virol       Date:  1983       Impact factor: 2.574

5.  Immunogenicity of purified glycoprotein gB of herpes simplex virus.

Authors:  Y Kino; T Eto; K Nishiyama; N Ohtomo; R Mori
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

6.  Latent HSV-1 infection in mice immunized with a zwitterionic detergent-extracted HSV-1 antigen preparation.

Authors:  A al-Ghamdi; R Jennings; H Bentley; C W Potter
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

7.  In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model.

Authors:  J I Sin; J J Kim; J D Boyer; R B Ciccarelli; T J Higgins; D B Weiner
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

8.  Animal studies on the efficacy of vaccination against recurrent herpes.

Authors:  M Scriba
Journal:  Med Microbiol Immunol       Date:  1982       Impact factor: 3.402

9.  Immune response to a DNA free herpes simplex vaccine in man.

Authors:  R Cappel; S Sprecher; F Rickaert; F de Cuyper
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

10.  Comparison of effects of adjuvants on efficacy of virion envelope herpes simplex virus vaccine against labial infection of BALB/c mice.

Authors:  T A Thomson; J Hilfenhaus; H Moser; P S Morahan
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.